Search results
Results From The WOW.Com Content Network
Alcon offices in Johns Creek, Georgia. Alcon Inc. ( German: Alcon AG) is a Swiss-American pharmaceutical and medical device company specializing in eye care products. It has a paper headquarters in Geneva, Switzerland but its operational headquarters are in Fort Worth, Texas, United States, where it employs about 4,500 people. [2]
Novartis and Viatris were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her body in the 1950s and used to fuel medical research and ...
Scam call centers operate in Ukraine, [1] [2] including major cities such as Kyiv and Dnipro. Under Article 190 of The Criminal Code of Ukraine, the activities of these call centers are considered illegal. [3] According to Sberbank, the "capital" of phone fraud is Dnipro, [4] and up to 95% of calls originate from Ukraine to Russians.
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York.The company was founded in 1988. [2] Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which ...
Alcon relocated its headquarters to Geneva in 2018, citing an opportunity to “increase Alcon’s global scale and reach to better serve customers.” The company employs a total of 25,000 people.
A man is filing a lawsuit against Walmart claiming that numerous items were more expensive at checkout than what was advertised on the shelf.
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
By Patrick Wingrove and Michael Erman. (Reuters) - Four pharmaceutical companies involved in the first U.S. negotiations over prices for the Medicare program said they do not expect a significant ...